OCA
ACET icon

Octagon Capital Advisors’s Adicet Bio ACET Stock Holding History

Octagon Capital Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-47,987
Closed -$929K – 43
2024
Q2 		$929K Hold
47,987
– – 0.15% 43
2024
Q1 		$1.8M Buy
+47,987
New +$1.99M 0.22% 54

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Octagon Capital Advisors's ACET Position: Q3 2024 in Review

Octagon Capital Advisors sold out of Adicet Bio (ACET) in Q3 2024, closing a stake of 47,987 shares — an estimated $929K sold.

Octagon Capital Advisors first reported a position in ACET in Q1 2024 and held it in 2 quarters. The position peaked at $1.8M in Q1 2024. 64 funds tracked by Wall St. Rank hold ACET as of Q3 2024.

  • Octagon Capital Advisors reported no remaining Adicet Bio position as of Q3 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 47,987 Adicet Bio shares in Q3 2024, an estimated $929K.
  • Octagon Capital Advisors first reported a position in Adicet Bio in Q1 2024 and held it in 2 quarters.
  • Octagon Capital Advisors's Adicet Bio position peaked at $1.8M in Q1 2024.
  • 64 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2024.

Based on Octagon Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.